September 7, 2005 | Posted by

Merck – Back of the Envelope Analysis

I played around with Merck’s financials this morning. It appears that MRK will be able to keep paying the dividend despite major blockbuster expirations (Zocor and Fosomax) without dipping substantially into its $13 billion war chest. Here is my back of the envelope analysis (excel spreadsheet).

Vitaliy N. Katsenelson, CFA

This article is written for educational purposes only. It is not intended as a recommendation to buy or sell securities. Author and/or his employer may have a position in the securities discussed in this article. Security positions may change at any time.

Bookmark and Share

Short URL: http://ContrarianEdge.com/?p=50

  • http://www.blogger.com/profile/11393547 Craig

    Interesting blog. While I focus mostly on the technology sector, a lot of your posts are very insightful (esp. the earnings game). Best of luck with your blog.

    -Craig
    http://techstockblog.blogspot.com/

  • http://www.blogger.com/profile/11393547 Craig

    do you have a rss feed? I was going to add your blog to my newsreader, but did not notice any type of sydication/rss feeds?

Recently Commented

  • Anonymous: Great story and I admire your work. Did you marry a Russian girl? Being married to a Russian girl and...
  • Christian Rivera: Also can Walmart grow eps 15%/yr like they did from 1996 to 2006?
  • Christian Rivera: Vitaliyk, do you think Walmart will increase margins more than 50% (3.5% to 5.3%) in the next...
  • McCoy Penninger: I really enjoyed reading this.  Dead on.
  • I Need Money: So I guess is we hear Hoenig say that “the Fed should stick to its mission as lender of last...

Recently Added